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The tumour suppressor gene RASSF1A is known to be frequently silenced by promoter hypermethylation in neuroblastoma tumours.
Here we explored the possible prognostic significance of aberrant promoter hypermethylation of RASSF1A in serum DNA samples of
patients with neuroblastoma as a surrogate marker for circulating tumour cells. We analysed the methylation status of the RASSF1A
gene in matched tumour and pretreatment serum DNA obtained from 68 neuroblastoma patients. Hypermethylation of RASSF1A in
tumour samples was found in 64 patients (94%). In contrast, serum methylation of RASSF1A was observed in 17 patients (25%).
Serum methylation of RASSF1A was found to be statistically associated with age X12 months at diagnosis (P¼0.002), stage 4
(Po0.001) and MYCN amplification (Po0.001). The influence of serum RASSF1A methylation on prognosis was found to be
comparable with that of the currently most reliable marker, MYCN amplification on univariate analysis (hazard ratio, 9.2; 95%
confidence interval (CI), 2.8–30.1; Po0.001). In multivariate analysis of survival, methylation of RASSF1A in serum had a hazard ratio
of 2.4 (95% CI, 0.6–9.2), although this association did not reach statistical significance (P¼0.194). These findings show that the
methylation status of RASSF1A in the serum of patients with neuroblastoma has the potential to become a prognostic predictor of
outcome.
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Neuroblastoma is the most common extracranial solid tumour in
children and is characterised by a wide range of clinical
behaviours, from spontaneous regression to rapid progression
with a fatal outcome (Maris et al, 2007). The clinical outcome is
associated with disease stage, age at diagnosis, MYCN amplifica-
tion and histological classification. Although numerous genetic
abnormalities, including MYCN amplification, are associated with
tumour progression and poor outcome, the molecular mechanisms
responsible for the pathogenesis of aggressive neuroblastoma
remain unclear. Identifying such molecular changes may con-
tribute to improved clinical management and outcome prediction
of newly diagnosed neuroblastomas.
In recent years, changes in the status of DNA methylation,
known as epigenetic alterations, have turned out to be one of the
most common molecular alterations in human neoplasia including
neuroblastoma (Misawa et al, 2005; Sugino et al, 2007). Several
potential tumour-suppressor genes have been described as
frequently silenced by hypermethylation in neuroblastomas.
Methylation of promoter CpG islands is known to inhibit
transcriptional initiation and cause permanent silencing of down-
stream genes. Loss of heterozygosity of chromosome 3p21.3 is one
of the most frequent alterations in solid tumours. Located within
this 3p21.3 locus, the RAS-association domain family 1, isoform
A gene (RASSF1A) encodes a RAS effector that has been identified
as a tumour suppressor of many different cancer types (Dammann
et al, 2000). RASSF1A falls into the category of genes frequently
inactivated by methylation rather than mutational events. This
gene is silenced and inactivated by promoter region hypermethy-
lation in many adult and childhood cancers, including neuro-
blastoma (Astuti et al, 2001; Harada et al, 2002; Wong et al, 2004;
Yang et al, 2004; Banelli et al, 2005; Lazcoz et al, 2006; Michalowski
et al, 2008). RASSF1A has been shown to play important roles in
cell cycle regulation, apoptosis and microtubule stability as a
tumour suppressor gene (Agathanggelou et al, 2005).
It is well known that DNA fragments are frequently and
abundantly found in the serum of cancer patients, with
significantly higher levels in patients with metastasis (Hesson
et al, 2007). A number of studies have evaluated the potential of
circulating tumour-related methylated DNA in serum for the
molecular diagnosis and prognosis of various types of cancer
(Mu ¨ller et al, 2003; Ibanez de Caceres et al, 2004; Mori et al, 2005).
Methylation-specific PCR assay is a sensitive and specific assay for
tumour-related DNA methylation in serum. Several studies have
investigated the prospect of using DNA methylation as a surrogate
marker for circulating tumour cells in serum samples from breast
cancer or melanoma patients (Fiegl et al, 2005; Koyanagi et al,
2006). However, no studies of neuroblastoma have assayed serum
samples for aberrant DNA methylation. Therefore, this study
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sinvestigated whether it is possible to detect RASSF1A epigenetic
alterations in the serum of neuroblastoma patients, and aberrant
RASSF1A methylation in patient pretherapeutic serum is of
prognostic significance in neuroblastoma using a series of matched
neuroblastoma tumour and serum DNA.
MATERIALS AND METHODS
Patients and sample collection
Clinical data were collected retrospectively by reviewing the
medical database at the Hospital of Kyoto Prefectural University
of Medicine for the period between 1985 and 2004. After approval
by the Institutional Review Board, 68 neuroblastoma patients were
identified on the basis of histological examination of tumour
specimens that met the following criteria: the patient had an
available tumour specimen; a serum specimen was available; and
the patient either died or had 41 year of follow-up time. The
clinical data included information regarding tumour stage, age at
diagnosis, sex, MYCN gene status and outcome. Staging was
evaluated according to the criteria of the International Neuro-
blastoma Staging System (Maris et al, 2007). Patients of any age
who had stage 1 or 2 disease and those younger than 12 months
with stage 3 or 4S disease were given either surgery or surgery with
chemotherapy (Matsumura and Michon, 2000). Patients aged 12
months or older with stage 3 and any patients with stage 4 disease
were treated according to the protocol by the Japanese Neuro-
blastoma Study Group (Sawaguchi et al, 1990; Tsuchida and
Kaneko, 2000; Kaneko et al, 2002; Suita et al, 2007). The patients
with stage 4 disease underwent high-dose chemotherapy with
autologous stem-cell rescue after the initial chemotherapy. Instead
of pre-specified sample size determination, power analysis was
conducted after collecting clinical data to guarantee statistical
power and to evaluate whether RASSF1A methylation is a
prognostic marker for survival. In a realistic scenario, a study of
68 patients had power of 96% to detect a single marker with hazard
ratio larger than 5.
Tumour samples at the time of diagnosis and before the
administration of chemotherapy were frozen immediately and
stored at  801C until DNA extraction. In addition, match-paired
serum samples were assessed. Peripheral blood was obtained
before any therapy or surgery. To avoid contamination of serum
DNA by the DNA from WBCs, serum was prepared exclusively
from the liquid fraction of clotted blood after centrifugation at
1000 g for 10min and stored it at  201C until DNA extraction.
For the extraction of free DNA, we used 200ml of stored serum,
which supplemented with 1mg salmon testes DNA (Sigma,
St Louis, MO, USA) as a carrier DNA. DNA was extracted from
tumour samples using a QIAmp DNA Mini Kit and from serum
samples using a QIAmp DNA Blood Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
Analysis of DNA methylation
Treatment of tumour DNA and serum DNA with sodium
bisulphite was performed with an EZ DNA methylation kit (Zymo
Research, Orange, CA, USA) following the protocol of the
manufacturer. Methylation-specific PCR was performed with
primers specific for either methylated or unmethylated DNA
spanning the region within the RASSF1A gene (Figure 1). The
primers used were methylation-specific RAM-1 (50-GTG
TTAACGCGTTGCGTATC-30) and RAM-2 (50-AACCCCGCGAACT
AAAAACGA-30) and unmethylation-specific RAU-1 (50-TTTGGT
TGGAGTGTGTTAATG-30) and RAU-2 (50-CAAACCCCACAAACT
AAAAACAA-30), as described earlier (Lo et al, 2001). PCR
conditions consisted of an initial incubation for 10min at 951C
followed by 35 cycles for tumour samples or 40 cycles for serum
samples of denaturation at 951C for 45s, annealing at 601C for 45s
and extension at 721C for 60s, followed by a final extension step of
721C for 10min. Lymphocyte DNA and in vitro methylated (using
SssI CpG methylase; New England Biolabs, Beverly, MA, USA)
lymphocyte DNA were used as unmethylated and methylated
controls, respectively. The PCR products obtained were analysed
by electrophoresis in 2% agarose gels and stained with ethidium
bromide. Samples were scored as methylation positive when
methylated alleles were visualised as bands in the methylated DNA
lane and as methylation negative when bands were seen only in the
unmethylated DNA lane. The analysis of the samples in this study
was performed by an analyst blinded to the clinical and biological
information.
Statistical analysis
The primary end point was overall survival defined by the period
from diagnosis of the primary tumour to any cause of death. The
relationship between clinicopathological variables and methylation
status of the RASSF1A gene was shown initially using contingency
tables and w
2 test. Survival curves for RASSF1A methylation were
derived by the Kaplan–Meier method. Univariate analysis was
conducted using Cox’s proportional hazard models and log-rank
test. Performance of RASSF1A methylation as a prognostic marker
was also analysed after adjustment for known prognostic factors
by (i) subset analysis of stage 3 patients using contingency tables
and Fisher’s exact test and (ii) multivariate Cox’s proportional
hazard models including age, sex and tumour stage. Two-sided
P-valueso0.05 were considered as significant. SAS 9.13 (SAS
Institute Inc., Cary, NC, USA) was used for statistical analyses.
RESULTS
A total of 124 patients with histologically confirmed neuroblastoma
or ganglioneuroblastoma were treated at the Hospital of Kyoto
Prefectural University of Medicine between January 1985 and May
2004. Sixty-eight patients met the criteria of this retrospective
study. The detailed patient disposition is shown in Figure 2 and the
baseline characteristics of patients are presented in Table 1. Of the
68 patients, 24 were classified as stage 1, 11 as stage 2, 11 as stage 3,
18 as stage 4 and 4 as stage 4S. At the time of diagnosis, 42 patients
(62%) were younger than 12 months, and 26 (38%) were older. We
found no significant differences between included and excluded
patients for age or stage statistically. Twelve patients (18%) had
tumours with MYCN amplification, and MYCN amplification was
not detected in the tumours from 56 (82%) patients by southern
RASSF1A
3p21.3 Cen Tel
56 12 3 4
1000bp CpG island
100 bp Exon 1
CpG
MSP



Figure 1 Genomic structure of the RASSF1A gene. Vertical tick marks,
CpG sites; blue boxes, exons; green box, CpG island in the promoter; red
box, region analysed by methylation-specific PCR.
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sblot analysis or fluorescence in situ hybridisation. The median
follow-up time was 72 months, with a range from 9 to 248 months.
Detection of RASSF1A promoter methylation in tumours
This study initially investigated the hypermethylation status of the
RASSF1A tumour suppressor genes in 68 neuroblastoma tumours.
Only four (one each at stage 1, 2, 4S and 3) tumours showed no
methylation of RASSF1A (Supplementary Table). All other
neuroblastoma tumours (64 of 68; 94%) showed methylated
RASSF1A. Hypermethylation in tumours was observed very
frequently in all of the stages of neuroblastoma examined,
including stage 1, 2 and 4S tumours (Supplementary Table) and
no correlation between RASSF1A methylation and known prog-
nostic factors including stage, age and MYCN amplification was
detected. No relationship between RASSF1A methylation in
tumours and outcome was also observed. RASSF1A methylation
was not observed in any of the three benign ganglioneuromas.
Detection of RASSF1A promoter methylation in serum
The hypermethylation status of RASSF1A in the matched serum
DNA samples was then determined and compared with the pattern
of hypermethylation found in the corresponding tumour DNA
samples (Figure 3). RASSF1A hypermethylation was detected in 17
of 68 (25%) matched serum DNA samples (Table 1). The detailed
overview is shown in Supplementary Table.
Correlation of serum RASSF1A methylation status with
clinical factors
The methylation status of RASSF1A in the pretherapeutic serum of
the 68 patients was analysed for association with known prognostic
factors (Table 2). Serum RASSF1A methylation showed
a significant statistical association with age X12 months
(P¼0.002). RASSF1A methylation in serum was detected more
frequently in disseminated stage 4 tumours than local-regional
(stage 1, 2 and 3) and 4S tumours (Po0.001). Furthermore, serum-
methylated RASSF1A was significantly correlated with MYCN
amplification (Po0.001). Notably, all cases with MYCN amplifica-
tion showed RASSF1A methylation of serum DNA (Supplementary
Table).
124 patients diagnosed as neuroblastoma and registered
68 patients met eligibility criteria
13 died
28 confirmed as alive
20 lost to follow-up  5 years after diagnosis 
7 lost to follow-up < 5 years after diagnosis
56 patients excluded 
because samples were not available 
or follow-up time was less than 1 year
<
Figure 2 Patient disposition.
Table 1 Characteristics of patients
Characteristic No. of patients (%)
Sex
Male 27 (39.7)
Female 41 (60.3)
Age at diagnosis
o12 months 42 (61.8)
X12 months 26 (38.2)
Stage
1 24 (35.3)
2 11 (16.2)
3 11 (16.2)
4 18 (26.5)
4S 4 (5.9)
MYCN
Non-amplified 56 (82.4)
Amplified 12 (17.6)
Diagnosis
GNB 7 (10.3)
NB 61 (89.7)
Serum RASSF1A
Unmethylated 51 (75.0)
Methylated 17 (25.0)
Case no. 2          3          25         26         27        30
Serum
U   M    U   M    U   M  U   M    U   M    U   M
Tumour
Tumour
Serum
Case no. 45       49         54      56        58         60
U   M    U   M    U   M  U    M   U   M    U   M
Figure 3 RASSF1A methylation status of tumour and serum DNA in
neuroblastoma patients. M, methylated; U, unmethylated. The sizes of the
PCR products for methylated and unmethylated primers are 93 and
105bp, respectively. (A) Cases stage 1 and 2 with good prognosis tumour
DNAs are methylated but absent in the serum DNAs. (B) In contrast, in
stage 3 and 4 MYCN-amplified cases, methylated DNAs are detected in
both tumour and serum samples.
Table 2 Associations between clinical factors and serum RASSF1A
methylation status
Characteristic
Methylated
no.
Unmethylated
no.
Total
no. P-value
Age at diagnosis 0.002
o12 months 5 37 42
X12 months 12 14 26
Stage o0.001
1/2/4S 3 36 39
33 8 1 1
41 1 7 1 8
MYCN o0.001
Non-amplified 5 51 56
Amplified 12 0 12
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methylation in serum
The association of pretherapeutic serum methylation status of
RASSF1A with clinical outcome was analysed in 68 patients with
known follow-ups. Univariate analyses revealed prognostic sig-
nificance for age at diagnosis X12 months, stage 4 and MYCN
amplification (P¼0.002, Po0.001 and Po0.001, respectively;
Table 3) in this cohort, as expected. Patients with serum-
methylated RASSF1A had significantly worse overall survival than
patients with serum-unmethylated RASSF1A (Po0.001, log-rank
test; Figure 4A). The 5-year survival was more than 90% in patients
without serum methylation of RASSF1A, whereas lower than 50%
in patients with serum methylation of RASSF1A (hazard ratio, 9.2;
95% confidence interval (95% CI), 2.8–30.1; Po0.001); Table 3).
RASSF1A methylation in serum and the known prognostic factors
were also correlated with relapse-free survival as well as with
overall survival (Po0.001; Table 4; Figure 4B). Furthermore, a
subset analysis revealed that stage 3 patients also had a trend
towards poorer prognosis when RASSF1A was methylated in
serum. When limited to cases in stage 3, two of the three patients
with serum-methylated RASSF1A died, whereas all eight patients
with serum-unmethylated RASSF1A are alive (P¼0.055, Fisher’s
exact test). In a multivariate analysis including age, sex and
tumour stage, serum RASSF1A methylation was still associated
with poor outcome with a hazard ratio of 2.4 (95% CI, 0.6–9.2),
although this did not reach statistical significance (P¼0.194;
Table 5).
DISCUSSION
In patients with malignancies, aberrant methylation of serum DNA
has been reported (Mu ¨ller et al, 2003; Ibanez de Caceres et al, 2004;
Fiegl et al, 2005; Mori et al, 2005; Koyanagi et al, 2006). We have
detected cell-free tumour DNA in serum of neuroblastoma patients
(Gotoh et al, 2005). Prognosis in stage 4 neuroblastoma patients
with metastases is poor despite intensive chemotherapy (Maris
et al, 2007). Therefore, this study aimed to explore the possible
prognostic significance of aberrant promoter hypermethylation of
RASSF1A, which has been found frequently in neuroblastoma
tumours, using pretherapeutic serum of neuroblastoma patients as
a surrogate marker for circulating tumour cells.
We first investigated the RASSF1A methylation status in 68
neuroblastoma tumour DNA samples in comparison with matched
serum DNA samples. The methylation of RASSF1A was observed in
this study in 94% of primary tumours. Our results show that
promoter hypermethylation of RASSF1A occurs at a high
frequency in primary neuroblastoma tumours and no correlation
between RASSF1A methylation and known prognostic factors
including stage, age and MYCN amplification, or outcome was
seen. The high proportion of RASSF1A promoter methylation in
tumours agrees with earlier reports in the literature, which have
found RASSF1A to be hypermethylated in 52–94% of tumour DNA
samples (Astuti et al, 2001; Harada et al, 2002; Wong et al, 2004;
Yang et al, 2004, 2007; Banelli et al, 2005; Lazcoz et al, 2006;
Michalowski et al, 2008). Several earlier studies with one exception
(Yang et al, 2004) failed to find a statistical correlation between
RASSF1A methylation in tumours and poor outcome (Astuti et al,
2001; Harada et al, 2002; Banelli et al, 2005; Michalowski et al,
2008). We also did not observe any relationship between RASSF1A
methylation in tumours and prognosis. RASSF1A hypermethyla-
tion in tumours can be a relatively early event in neuroblastoma
tumorigenesis as it is detectable in non-advanced early-stage
tumours with high frequency. Although the prognostic significance
of epigenetic changes of single genes in neuroblastoma tumour
DNA remain controversial, a few studies have indicated that poor
prognosis is associated with the CpG island methylator phenotype
Table 3 Univariate analysis of survival
Characteristic Hazard ratio 95% CI P-value
Age at diagnosis
o12 months Reference
X12 months 23.6 3.1–181.9 0.002
Sex
Male Reference
Female 1.0 0.3–3.0 0.983
Stage
1/2/3/4S Reference
4 19.8 4.4–89.5 o0.001
MYCN
Non-amplified Reference
Amplified 8.2 2.7–24.7 o0.001
Serum RASSF1A
Unmethylated Reference
Methylated 9.2 2.8–30.1 o0.001
CI¼confidence interval.
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Figure 4 Kaplan–Meier survival curves of 68 neuroblastoma patients:
correlation of pretherapeutic serum RASSF1A methylation status with
overall survival (A) and relapse-free survival (B). M, methylated: patients
with serum methylation of RASSF1A. U, unmethylated: patients without
serum methylation of RASSF1A. The 5-year overall survival was more than
90% in patients without methylation, whereas lower than 50% in patients
with methylation (Po0.001).
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that aberrant methylation of multiple genes is likely to contribute
to neuroblastoma pathogenesis.
As a next step, we analysed RASSF1A methylation status in 68
paired serum DNA samples. In contrast to tumours, RASSF1A
methylation was detected in neuroblastoma patient serum from
only 25% (17 out of 68). To investigate the clinical significance of
the serum RASSF1A methylation, associations with established
prognostic factors and outcome were evaluated. RASSF1A
methylation in serum was found to be statistically associated with
established prognostic factors. Serum RASSF1A methylation was
more frequently detected in neuroblastoma patients with age X12
months at diagnosis (P¼0.002), stage 4 (Po0.001) and MYCN
amplification (Po0.001). Furthermore, the presence of methyla-
tion of RASSF1A in serum was associated with poorer outcome.
The influence of serum RASSF1A methylation on prognosis was
found to be comparable with that of the currently most reliable
marker, MYCN amplification in univariate analysis. A subset
analysis of stage 3 patients showed a trend associating poor
survival with serum RASSF1A methylation (P¼0.055), although
the data were limited due to the small number of patients in the
subgroup. In multivariate analysis of survival, methylation of
RASSF1A in serum had a hazard ratio of 2.42, but this association
did not reach statistical significance (P¼0.194). Further validation
studies using a larger set of patients are necessary to confirm our
findings.
The presence of tumour-derived DNA within the blood stream
has been identified earlier (Mu ¨ller et al, 2003; Fiegl et al, 2005;
Mori et al, 2005). Recently, one study showed that the detection of
circulating tumour cells was correlated with tumour-related
methylated DNA in patients with melanoma (Koyanagi et al,
2006), suggesting that circulating tumour cells are a potential
source of circulating methylated DNA. Our study suggests that
methylated RASSF1A DNA in serum is a surrogate marker for
circulating neuroblastoma cells. Another recently published study
showed that RASSF1A methylation was also detectable in ovarian
cancer patient’s serum at a high frequency from methylated
tumour cases including several stage I tumours (Ibanez de Caceres
et al, 2004). In the earlier study, there was no statistical association
between tumour stage and positive detection in serum. However,
some other studies have shown limited detection of RASSF1A
methylation in the serum of patients with other neoplasms
(Murray et al, 2004; Hesson et al, 2007). These differing results
may suggest that free neoplastic DNA from ovarian cancer can
access the blood stream more readily than that from other
neoplasms including neuroblastoma.
In conclusion, this is the first study to examine epigenetic
changes in a tumour suppressor gene, RASSF1A, the promoter of
which is hypermethylated at a high frequency in neuroblastoma
tumours, using serum DNA in a cohort of neuroblastoma patients.
This study demonstrates the utility of detecting circulating
methylated RASSF1A, which can be measured in serum, as a
potentially predictive marker of neuroblastoma outcome. RASS-
F1A methylation in serum could have useful clinical applications
in neuroblastoma management, if our results are confirmed in
larger studies. However, we should not forget the limitation when
attempting to translate our findings into the clinical fields as highly
sensitive methylation analysis could be tricky because of
incomplete bisulphite conversion by inexperienced analysts.
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